IMR Press / EJGO / Volume 34 / Issue 4 / pii/1630906371563-1112115535

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Impact of multimodal therapy on the survival of patients with newly diagnosed uterine carcinosarcoma
Show Less
1 Department of Gynecology, Cancer Institute Hospital, Kotou-Ku (Japan)
Eur. J. Gynaecol. Oncol. 2013, 34(4), 291–295;
Published: 10 August 2013

Purpose: To investigate treatment outcomes of uterine carcinosarcoma (CS) patients who underwent complete surgical resection of all visible disease and platinum-based adjuvant chemotherapy (multimodal therapy). Materials and Methods: The authors reviewed 127 uterine CS patients treated at this institution from 1990 to 2010. They operated 123 patients in clinical Stages 1-3, 97 of which underwent complete resection and systemic lymphadenectomy. Results: A total of 97 patients (FIGO 2008: Stage 1 in 50 patients, Stage 2 in six, Stage 3 in 37, and Stage 4 in four) underwent surgical staging, 74 of which were administered five cycles (median) of platinumbased adjuvant chemotherapy. The median overall survival (OS) associated with multimodal therapy 50.6 months compared with 34.9 months incomplete multimodal therapy. After multimodal treatment, 32.9% (32/97) patients showed recurrence (24/32 hematogenous). Conclusion: Multimodal therapy increased survival among uterine CS patients, but the recurrence rate remained high. Further consideration of treatment options for uterine CS is required.
Uterine carcinosarcoma
Multimodal therapy
Prognostic factor
Back to top